The estimated Net Worth of David S Tierney is at least $7.23 million dollars as of 21 August 2024. David Tierney owns over 15,000 units of Catalyst Pharmaceuticals Inc stock worth over $7,080,988 and over the last 19 years he sold CPRX stock worth over $0. In addition, he makes $148,064 as Independent Director at Catalyst Pharmaceuticals Inc.
Sign up
David Tierney CPRX stock SEC Form 4 insiders trading
David has made over 27 trades of the Catalyst Pharmaceuticals Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of CPRX stock worth $60,150 on 21 August 2024.
The largest trade he's ever made was buying 100,000 units of Catalyst Pharmaceuticals Inc stock on 19 September 2018 worth over $20,000. On average, David trades about 8,164 units every 90 days since 2006. As of 21 August 2024 he still owns at least 363,874 units of Catalyst Pharmaceuticals Inc stock.
You can see the complete history of David Tierney stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Tierney biography
Dr. David S. Tierney, M.D. serves as Independent Director of Catalyst Pharmaceutical Partners, Inc. Dr. Tierney currently serves as Chief Executive Officer of Pharma2B, a privately held clinical stage pharmaceutical company. From September 2018 until January 2020, Dr. Tierney served as President & CEO of BioPharmX Corporation, a dermatology specialty pharmaceutical company. From January 2014 until March 2018, he served as President & CEO of Icon Bioscience, Inc., a privately held ophthalmic drug delivery company. Dr. Tierney served as President and Chief Operating Officer (and a member of the board of directors) of Oceana Therapeutics, Inc., a private specialty pharmaceutical company between the organization of that company in 2008 and the sale of that company to Salix Pharmaceuticals, Ltd. in December 2011. Dr. Tierney also served as the President and CEO (and as a member of the board of directors) of Valera Pharmaceuticals, Inc. a specialty pharmaceutical company, between August 2000 and April 2007, when Valera completed a merger with Indevus Pharmaceuticals, Inc. Further, from January 2000 to August 2000, Dr. Tierney served as President of Biovail Technologies, a division of Biovail Corporation, a Canadian drug delivery company, where he was responsible for all of Biovail’s research and development, regulatory and clinical activities. Finally, from March 1997 to January 2000, Dr. Tierney was Senior Vice President of Drug Development at Roberts Pharmaceutical Corporation, where he was responsible for all research and development activities, and for drug development, medical affairs, worldwide regulatory affairs and chemical process development, as well as being part of the executive management team, and from December 1989 to March 1997, Dr. Tierney was employed by Élan Corporation, a pharmaceutical company, in a variety of management positions. Dr. Tierney received his medical degree from the Royal College of Surgeons in Dublin, Ireland and was subsequently trained in internal medicine.
What is the salary of David Tierney?
As the Independent Director of Catalyst Pharmaceuticals Inc, the total compensation of David Tierney at Catalyst Pharmaceuticals Inc is $148,064. There are 12 executives at Catalyst Pharmaceuticals Inc getting paid more, with Patrick McEnany having the highest compensation of $3,371,560.
How old is David Tierney?
David Tierney is 56, he's been the Independent Director of Catalyst Pharmaceuticals Inc since 2002. There are 11 older and 4 younger executives at Catalyst Pharmaceuticals Inc. The oldest executive at Catalyst Pharmaceuticals Inc is Charles O'Keeffe, 80, who is the Lead Independent Director.
What's David Tierney's mailing address?
David's mailing address filed with the SEC is 355 ALHAMBRA CIRCLE, SUITE 801, , CORAL GABLES, FL, 33134.
Insiders trading at Catalyst Pharmaceuticals Inc
Over the last 18 years, insiders at Catalyst Pharmaceuticals Inc have traded over $35,595,986 worth of Catalyst Pharmaceuticals Inc stock and bought 7,401,098 units worth $7,307,159 . The most active insiders traders include Pharmaceutical Inc Biomarin, Patrick J Mcenany et Steve Miller. On average, Catalyst Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $1,097,019. The most recent stock trade was executed by David S Tierney on 21 August 2024, trading 15,000 units of CPRX stock currently worth $60,150.
What does Catalyst Pharmaceuticals Inc do?
catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso
What does Catalyst Pharmaceuticals Inc's logo look like?
Complete history of David Tierney stock trades at Catalyst Pharmaceuticals Inc, Zevra Therapeutics Inc et BioPharmX
Catalyst Pharmaceuticals Inc executives and stock owners
Catalyst Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Patrick McEnany,
Chairman of the Board, President, Chief Executive Officer -
Steven Miller,
Chief Operating Officer, Chief Scientific Officer -
Gary Ingenito,
Chief Medical Officer and Head of Regulatory Affairs -
Patrick J. McEnany,
Co-Founder, Chairman, Pres & CEO -
Dr. Steven R. Miller,
COO & Chief Scientific Officer -
Dr. Gary Ingenito,
Chief Medical & Regulatory Officer -
Alicia Grande,
Chief Accounting Officer, VP, Treasurer & CFO -
Alicia Grande,
Chief Financial Officer, Vice President, Treasurer -
Jeffrey Del Carmen,
Chief Commercial Officer -
Brian Elsbernd,
Chief Compliance Officer, Chief Legal Officer -
Charles O'Keeffe,
Lead Independent Director -
Donald Denkhaus,
Independent Director -
David Tierney,
Independent Director -
Richard Daly,
Independent Director -
Jeffrey Del Carmen,
Chief Commercial Officer -
Philip B. Schwartz,
Corp. Sec. -
Dr. Preethi Sundaram Ph.D.,
Chief Product Devel. Officer -
Pete Curry Sr.,
VP of Sales -
Brian Elsbernd J.D.,
Chief Compliance Officer & Chief Legal Officer -
Mary Coleman,
VP & Head of Investor Relations -
Philip H Coelho,
Director -
Paul J Merrigan,
Chief Commercial Officer -
M Douglas Winship,
V.P. of Regulatory Operations -
Daniel Brennan,
Chief Commercial Officer -
Tamar Thompson,
Director -
David D Muth,
Exec. V.P., Corp. Development -
Hubert E Md Huckel,
Director -
Milton J Wallace,
Director -
Pharmaceutical Inc Biomarin,
10% owner -
Jack Weinstein,
V.P., Treasurer & CFO -
Molly Harper,
Director -
Preethi Sundaram,
Chief Strategy Officer -
Steve Miller,
Chief Op. & Scientific Officer